Imugene share price
WebPrice trends tend to persist, so it's worth looking at them when it comes to a share like Imugene. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by-32.6%. As of the last closing price of AU$0.14, shares in Imugene were trading-24.26% below their 200 day moving average. WebDec 11, 2015 · Imugene Cancer Immunotherapies. @TeamImugene. ·. Sep 9. Leslie Chong's interview with Proactive provides extra detail about our ASX news of dosing our first patient in the phase 2 trial of nextHERIZON …
Imugene share price
Did you know?
WebImugene Limited Follow Share $0.12 Mar 14, 3:07:39 PM GMT+11 · AUD · ASX · Disclaimer search Compare to Immutep Ltd $0.26 IMM1.89% Sayona Mining Ltd $0.21 SYA8.00% … WebIMU chart Today 7.14% Week 20.00% 1 month 11.11% 6 months −21.05% Year to date 0.00% 1 year −40.00% 5 years 420.65% All time −93.25% Key stats Market capitalization 963.456M AUD Dividends yield (FY) — Price to earnings Ratio (TTM) — Basic EPS (TTM) −0.005 AUD About IMUGENE LIMITED ISIN AU000000IMU9 Sector Health Technology Industry …
WebJun 4, 2024 · Replimune currently has a market cap of US$ 740 million, $20.15 per share, so over $1 billion Aussie. Replimune currently has broker research /price targets of between $22 -$30 per share from analysts at JPMorgan, Roth Capital, Wainwright, Barclays . Ie median valuation of US$870 million WebImugene Limited (IUGNF) Stock Price & News - Google Finance Home IUGNF • OTCMKTS Imugene Limited Follow Share $0.10 Apr 3, 10:46:34 AM GMT-4 · USD · OTCMKTS · Disclaimer search Compare to...
WebImugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and … WebImugene is a clinical-stage immuno-oncology company developing cancer treatments. Founding Date. Founding Date. 2010. Founding Date. 2024. Founding Date. 2002. Founding Date. 2024. Founding Date. 2013. Type. ... Share price data provided by IEX. Company directory. Search directory ...
WebMay 23, 2024 · In reality, things have only improved from our share price peak last year. Allow us to remind you about the company you are a shareholder in. Imugene is as strong as it has ever been as we continue to make good progress. We have $100 million in cash making us one of the most financially secure biotechs on the ASX
WebApr 12, 2024 · Imugene - IMU Stock Forecast, Price & News Compare Today's Range N/A 50-Day Range N/A 52-Week Range N/A Volume 12.70 million shs Average Volume N/A … resoluute banjoWebJul 27, 2024 · Since March the company has surged from a share price of only 10¢ to 33¢, having climbed as high as 50¢ in May. Despite still being pre-revenue, the business is now valued at $1.6 billion. resonac japanWebPrice: Single User License: US $ 3260 . Corporate User License: US $ 6520 . Buy Now. Like . Inquire for Discount Download PDF Request Sample. Report Description; Table of Contents; The Nucleic Acid-based Drugs market revenue was XX Million USD in 2024, and will reach XX Million USD in 2028, with a CAGR of XX% during 2024-2028. resolve 17 project don\u0027t openWebApr 14, 2024 · Imugene - IMU News Today Compare Today's Range N/A 50-Day Range N/A 52-Week Range N/A Volume 12.70 million shs Average Volume N/A Market Capitalization N/A P/E Ratio N/A Dividend Yield N/A Price Target N/A Profile Chart Competitors Insider Trades Headlines Get Imugene News Delivered to You Automatically News Sentiment … resolution prevod na srpskiWebSep 1, 2024 · The Imugene Ltd [ASX:IMU] share price is floundering today on the back of an announcement regarding its HER-Vaxx immunotherapy in HER-2 positive gastric cancer trial. In early morning trade, IMU’s share price fell as low as 7%. Since then, it has rebounded slightly and is now down 4% at time of writing. Source: TradingView.com resonance hrvatskiWebAug 25, 2024 · Its share price surged over 20x in less than 24 months – from 3c in early 2024 to 67c by November 2024 – taking the valuation to an eye-watering $3.3 billion and earning the company ‘unicorn’ status. It also made Imugene the second-biggest ASX drug developer by market cap, behind only CSL. resonac koreaWebMar 26, 2024 · It hasn't been the best quarter for Imugene Limited ( ASX:IMU) shareholders, since the share price has fallen 10% in that time. But that doesn't change the fact that the … resolva path \u0026 drive